What is Ligand Pharmaceuticals Price-to-Operating-Cash-Flow?
As of today (2024-05-04), Ligand Pharmaceuticals's share price is €66.00.
Ligand Pharmaceuticals's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was €2.59. Hence, Ligand Pharmaceuticals's Price-to-Operating-Cash-Flow Ratio for today is 25.48.
The historical rank and industry rank for Ligand Pharmaceuticals's Price-to-Operating-Cash-Flow or its related term are showing as below:
FRA:LGDN'
s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.88 Med: 26.81 Max: 757.66
Current: 26.05
During the past 13 years, Ligand Pharmaceuticals's highest Price-to-Operating-Cash-Flow Ratio was 757.66. The lowest was 6.88. And the median was 26.81.
Ligand Pharmaceuticals's Cash Flow from Operations per share for the
three
months ended in Dec. 2023 was €0.42.
Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was €2.59.
During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Ligand Pharmaceuticals was -65.80% per year.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -4.90% per year.
During the past 13 years, Ligand Pharmaceuticals's highest 3-Year average Operating Cash Flow per Share Growth Rate was 526.40% per year. The lowest was -26.20% per year. And the median was 35.55% per year.
Ligand Pharmaceuticals Price-to-Operating-Cash-Flow Historical Data
The historical data trend for Ligand Pharmaceuticals's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ligand Pharmaceuticals Price-to-Operating-Cash-Flow Chart
|
Ligand Pharmaceuticals Annual Data
|
|
Trend |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Price-to-Operating-Cash-Flow |
|
Get a 7-Day Free Trial
|
|
|
- |
19.12 |
21.08 |
8.17 |
25.58 |
|
Ligand Pharmaceuticals Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Price-to-Operating-Cash-Flow |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
8.17 |
10.59 |
11.54 |
10.91 |
25.58 |
Competitive Comparison of Ligand Pharmaceuticals's Price-to-Operating-Cash-Flow
For the Biotechnology subindustry, Ligand Pharmaceuticals's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ligand Pharmaceuticals's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ligand Pharmaceuticals's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Ligand Pharmaceuticals's Price-to-Operating-Cash-Flow falls into.
Ligand Pharmaceuticals Price-to-Operating-Cash-Flow Calculation
Ligand Pharmaceuticals's Price-to-Operating-Cash-Flow ratio for today is calculated as
| Price-to-Operating-Cash-Flow Ratio | = | Share Price | / | Cash Flow from Operations per share (TTM) |
| = | 66.00 | / | 2.59 |
| = | 25.48 |
Ligand Pharmaceuticals's Share Price of today is €66.00.
Ligand Pharmaceuticals's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.59.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).
It can also be calculated from the numbers for the whole company:
Ligand Pharmaceuticals (FRA:LGDN) Business Description
Traded in Other Exchanges
Address
3911 Sorrento Valley Boulevard, Suite 110, San Diego, CA, USA, 92121
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
Ligand Pharmaceuticals (FRA:LGDN) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:LGDN has been successfully added to your